Welcome to our dedicated page for Healthwarehouse news (Ticker: HEWA), a resource for investors and traders seeking the latest updates and insights on Healthwarehouse stock.
HealthWarehouse.com, Inc. (OTCQB: HEWA) is a healthcare e‑commerce and technology company that regularly publishes detailed financial and operational updates. As an NABP Approved Digital Pharmacy based in Florence, Kentucky, HealthWarehouse.com reports on its performance in selling and delivering prescription and over‑the‑counter medications to customers in all 50 states, serving both direct‑to‑consumer and partner services (B2B) channels.
On this page, readers can follow HEWA news that covers quarterly and annual results, trends in prescription and over‑the‑counter sales, and management’s commentary on business drivers. Company releases discuss net sales, gross profit, operating expenses, net income or loss, and non‑GAAP measures such as EBITDA and Adjusted EBITDA, along with explanations of how product mix and partner services margins affect these figures.
HealthWarehouse.com’s news flow often highlights the impact of GLP‑1 medications on its results, including brand and compounded GLP‑1 prescriptions fulfilled through its partner services and direct‑to‑consumer businesses. The company also reports on technology initiatives, such as new pharmacy software and a proprietary e‑commerce platform, and how these investments relate to patient experience, operational efficiency, and scalability.
Investors and observers can use this news feed to review management’s discussion of topics like cold‑chain shipping capabilities, changes in over‑the‑counter marketplace sales, and the evolution of its B2B partner services pipeline. For ongoing insight into HealthWarehouse.com’s operating trends, financial performance, and strategic focus areas, this HEWA news page aggregates the company’s latest publicly released updates.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
HealthWarehouse.com, Inc. (OTCQB:HEWA) reported a 12% increase in net sales for 2022, totaling $18,142,633 driven by significant growth in partner services revenue. However, the company experienced a net loss of $952,029, worsening from $572,502 in 2021. Despite this, HealthWarehouse.com achieved positive cash flow for the sixth consecutive year with an Adjusted EBITDA of $146,787. Direct-to-consumer sales declined by 3.5%, while partner services revenue nearly doubled. Operating expenses rose by 10.7% to $12,725,433, largely due to increased shipping and salaries. The company plans to launch a new e-commerce platform in 2023.
HealthWarehouse.com, Inc. (OTC:HEWA) reported net sales of $4,681,302 for Q3 2022, an 11% increase from Q3 2021, driven by growth in partner services. The company recorded a loss from operations of $225,614, yet reported positive cash flow with an Adjusted EBITDA of $47,673. Prescription sales increased by 6.4% to $3,873,323, and OTC sales surged 46.2% to $736,265. Despite higher gross profit, operating expenses rose by 11.2%, leading to net losses slightly widening compared to last year. Future plans include launching a proprietary e-commerce platform aimed at improving customer retention.
HealthWarehouse.com, Inc. (OTC:HEWA) reported a 6% revenue increase in Q2 2022, totaling $4,199,832, driven by growth in partner services. However, the company experienced operational losses of $293,524 for the quarter and $507,512 for the first half of the year. Prescription sales rose by 4.5%, while over-the-counter sales jumped by 18.1%. Despite the revenue growth, gross margins declined slightly, and operating expenses increased by nearly 10%. The company is planning to launch a new e-commerce platform in Q4 2022 and has been recognized as a Top Workplace in Greater Cincinnati.
HealthWarehouse.com (OTC:HEWA) reported a 13% increase in revenues, totaling $4,314,980 for Q1 2022, driven by strong partner services and direct-to-consumer sales. Despite a reported operating loss of $213,988, the company achieved positive cash flow of $64,047 as per Adjusted EBITDA. Gross profit increased by $198,460 (7.5%), albeit with a declining gross margin of 66.1%. Operating expenses rose by 10.3% to $3,022,021, influenced by increased salaries and marketing costs. The company was recognized by Consumer Reports for its full range of prescription offerings.
HealthWarehouse.com (OTCQB: HEWA) reported 2021 net sales of $16,143,906, a 6% decrease from 2020, despite a 2% increase in prescription sales driven by partner services revenue.
The company posted a loss from operations of $572,502, but achieved positive cash flow for the fifth consecutive year with an Adjusted EBITDA of $459,208. Over-the-counter sales fell by 36.7%, influenced by reduced consumer demand post-COVID-19 peaks.
Looking ahead, the company plans to launch a new e-commerce platform in early 2022 to enhance customer experience and services.
HealthWarehouse.com (OTCQB: HEWA) reported a net sales increase of 5% to $4,212,127 for Q3 2021, with prescription sales up 13%. The company posted a loss from operations of $181,031 but achieved positive cash flow with an Adjusted EBITDA of $89,797. The decline in over-the-counter sales by 27% was attributed to decreased website traffic compared to pandemic highs in 2020. Despite the challenges, HealthWarehouse.com plans to expand B2B offerings and invest in technology to enhance customer experience.